Crystalline DMT Salt Forms for Solubility and Stability

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

N,N-dimethyltryptamine (DMT) free base has low melting point, low solubility in water, and fast degradation rate, making it challenging for effective drug formulation and bioavailability, particularly for neurological diseases.

Innovation Solution

Development of novel DMT salt forms such as fumarate, succinate, malate, sulfate, and oxalate crystalline forms with improved melting points, aqueous solubility, and hygroscopicity, including processes for their preparation and incorporation into pharmaceutical compositions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If DMT free base is used, then therapeutic activity is maintained, but melting point is low and solubility in water is extremely low

Engineering Contradiction:

Improveaqueous solubilityVSAvoidmelting point

Core Design Contradiction:

Quantity of substanceVSTemperature

Solution Approach 1:

The patent changes the chemical form of DMT from free base to salt forms (fumarate, succinate, malate, oxalate, sulfate, phosphate), which fundamentally alters its physicochemical properties including melting point and solubility characteristics

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces salt forming acids (fumaric acid, succinic acid, malic acid, oxalic acid, sulfuric acid, phosphoric acid) as intermediaries to convert DMT free base into salt forms that have improved pharmacokinetic properties

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If DMT free base is stored at room temperature, then convenience is improved, but degradation rate is fast

Engineering Contradiction:

ImprovestabilityVSAvoidstorage time

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent changes the chemical form from free base to salt forms, which significantly improves stability and reduces degradation rate, allowing storage at higher temperatures without loss of potency

Inventive Principle:

Principle #35Parameter changes

3Productivity

If DMT free base is used, then simplicity is maintained, but bioavailability is poor

Engineering Contradiction:

ImprovebioavailabilityVSAvoidformulation complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent changes the chemical form to salt forms that have improved bioavailability and pharmacokinetic properties, enabling better absorption and reduced first-pass metabolism

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20250388538A1N,n-dimethyltryptamine salts and crystalline salt forms

Publication Date: 2025.12.25 ATAI THERAPEUTICS INC

AI summary

This disclosure provides N,N-dimethyltryptamine salts and crystalline salt forms, their preparation, pharmaceutical compositions comprising said salts and crystalline salt forms, and their use in treating neurological diseases and conditions.